Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Dillon

Showing results (71-80 of 101) with videos related to

Pageof 11
Sort By:
The Lancet. Haematology|April 30, 2025
Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trialsNicola Potter, Jelena Jovanovic, Adam Ivey, et al.
Blood Advances|January 17, 2023
T-cell replete cord transplants give superior outcomes in high-risk and relapsed/refractory pediatric myeloid malignancyClaire Horgan, Khushnuma Mullanfiroze, Archana Rauthan, et al.
Blood|March 26, 2015
Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemiaAndrea Kühnl, Peter J M Valk, Mathijs A Sanders, et al.
Blood Advances|September 23, 2021
Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemiaIng S Tiong, Richard Dillon, Adam Ivey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2020
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid LeukemiaCharles Craddock, Aimee Jackson, Justin Loke, et al.
Blood Advances|September 8, 2022
Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentationHarry J Iland, Nigel Russell, Richard Dillon, et al.
Neoplasia (New York, N.Y.)|March 17, 2026
CCAAT-enhancer binding protein delta functions as a tumor suppressor gene in acute myeloid leukemiaSubhash C Prajapati, Cem Meydan, Yaseswini Neelamraju, et al.
Blood|May 1, 2024
Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AMLJad Othman, Nicola Potter, Adam Ivey, et al.
Nature Communications|August 8, 2022
Unified classification and risk-stratification in Acute Myeloid LeukemiaYanis Tazi, Juan E Arango-Ossa, Yangyu Zhou, et al.
Blood Cancer Journal|October 31, 2021
A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemiaJoshua F Zeidner, Tara L Lin, Carlos E Vigil, et al.
Pageof 11

Showing results (71-80 of 101) with videos related to

Sort By:
Pageof 11
The Lancet. Haematology|April 30, 2025
Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trialsNicola Potter, Jelena Jovanovic, Adam Ivey, et al.
Blood Advances|January 17, 2023
T-cell replete cord transplants give superior outcomes in high-risk and relapsed/refractory pediatric myeloid malignancyClaire Horgan, Khushnuma Mullanfiroze, Archana Rauthan, et al.
Blood|March 26, 2015
Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemiaAndrea Kühnl, Peter J M Valk, Mathijs A Sanders, et al.
Blood Advances|September 23, 2021
Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemiaIng S Tiong, Richard Dillon, Adam Ivey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2020
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid LeukemiaCharles Craddock, Aimee Jackson, Justin Loke, et al.
Blood Advances|September 8, 2022
Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentationHarry J Iland, Nigel Russell, Richard Dillon, et al.
Neoplasia (New York, N.Y.)|March 17, 2026
CCAAT-enhancer binding protein delta functions as a tumor suppressor gene in acute myeloid leukemiaSubhash C Prajapati, Cem Meydan, Yaseswini Neelamraju, et al.
Blood|May 1, 2024
Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AMLJad Othman, Nicola Potter, Adam Ivey, et al.
Nature Communications|August 8, 2022
Unified classification and risk-stratification in Acute Myeloid LeukemiaYanis Tazi, Juan E Arango-Ossa, Yangyu Zhou, et al.
Blood Cancer Journal|October 31, 2021
A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemiaJoshua F Zeidner, Tara L Lin, Carlos E Vigil, et al.
Pageof 11